Firsocostat (BioDeep_00000839787)
代谢物信息卡片
化学式: C28H31N3O8S (569.1831766)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(SC2=C1C(=O)N(C(=O)N2CC(C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5
InChI: InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1
描述信息
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor
Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.
同义名列表
4 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mohamad Dandan, Julia Han, Sabrina Mann, Rachael Kim, Kelvin Li, Hussein Mohammed, Jen-Chieh Chuang, Kaiyi Zhu, Andrew N Billin, Ryan S Huss, Chuhan Chung, Robert P Myers, Marc Hellerstein. Acetyl-CoA Carboxylase Inhibitor Increases LDL-apoB Production Rate in NASH with Cirrhosis: Prevention by Fenofibrate.
Journal of lipid research.
2023 Feb; ?(?):100339. doi:
10.1016/j.jlr.2023.100339. [PMID: 36737040] - Pradeep Kayampilly, Nancy Roeser, Thekkelnaycke M Rajendiran, Subramaniam Pennathur, Farsad Afshinnia. Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.
Metabolites.
2022 Oct; 12(10):. doi:
10.3390/metabo12100940. [PMID: 36295842] - Brian J Kirby, Justin D Lutz, Mun Sang Yue, Kimberly L Garrison, Ann Ran-Ran Qin, Lorraine Ampaw, Carine Beysen, Robert P Myers, Brian P Kearney, Anita Mathias. Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
Clinical pharmacology and therapeutics.
2021 05; 109(5):1334-1341. doi:
10.1002/cpt.2105. [PMID: 33141923] - Suzanna L Attia, Samir Softic, Marialena Mouzaki. Evolving Role for Pharmacotherapy in NAFLD/NASH.
Clinical and translational science.
2021 01; 14(1):11-19. doi:
10.1111/cts.12839. [PMID: 32583961] - F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Journal of medicinal chemistry.
2020 05; 63(10):5031-5073. doi:
10.1021/acs.jmedchem.9b01701. [PMID: 31930920] - Naim Alkhouri, Eric Lawitz, Mazen Noureddin, Ralph DeFronzo, Gerald I Shulman. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Expert opinion on investigational drugs.
2020 Feb; 29(2):135-141. doi:
10.1080/13543784.2020.1668374. [PMID: 31519114] - Mitsuharu Matsumoto, Hiroaki Yashiro, Hitomi Ogino, Kazunobu Aoyama, Tadahiro Nambu, Sayuri Nakamura, Mayumi Nishida, Xiaolun Wang, Derek M Erion, Manami Kaneko. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
PloS one.
2020; 15(1):e0228212. doi:
10.1371/journal.pone.0228212. [PMID: 31990961] - Eric J Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo, Bryan J McColgan, Jacqueline M Tarrant, Tuan Nguyen, Ling Han, Chuhan Chung, Adrian S Ray, John G McHutchison, G Mani Subramanian, Robert P Myers, Michael S Middleton, Claude Sirlin, Rohit Loomba, Edna Nyangau, Mark Fitch, Kelvin Li, Marc Hellerstein. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2018 12; 16(12):1983-1991.e3. doi:
10.1016/j.cgh.2018.04.042. [PMID: 29705265] - Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric J Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M Tarrant, Bryan J McColgan, Chuhan Chung, Adrian S Ray, G Mani Subramanian, Robert P Myers, Michael S Middleton, Michelle Lai, Michael Charlton, Stephen A Harrison. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology.
2018 11; 155(5):1463-1473.e6. doi:
10.1053/j.gastro.2018.07.027. [PMID: 30059671]